EN DE
Watch Novolog Pharm-Up 1966 Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Novolog Pharm-Up 1966 Ltd (NVLG) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Novolog Pharm-Up 1966 Ltd stock ILS 0.29, price ILS 0.78, that is 63.0% below the price, quality 44 out of 100. Rating: strongly overvalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare Il · ISIN IL0011401515

NP Novolog Pharm-Up 1966 Ltd logo Thin data Nov 8, 2026

Novolog Pharm-Up 1966 Ltd

NVLG · TA
Very expensive, weak quality

Our calculation puts a fair price 63% below what the stock costs today.

Low debt
Quality 44/100
Expensive Growth (revenue 5y +9.8 %/yr in ILS)
Loss over the last twelve months · 0.0% net margin (TTM) · fiscal year 2025 0.2%
Costs 67 times its yearly profit.
Fair value 0.2900 ILS · Strongly overvalued (−63.0%)
Negative free cash flow
Trails peers (3/13)
Narrow moat 19/100 · thin data
Thin data
Watch Novolog Pharm-Up 1966 Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

3.25 ILS 0.6680 ILS Fair Value 0.2900 ILS Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range 0.6680 ILS – 3.25 ILS · fair‑value band 0.2100 ILS – 0.3600 ILS · the 0.7830 ILS price screens above the 0.2900 ILS fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 8, 2026.

Follow Novolog Pharm-Up 1966 in your weekly email

Every Wednesday you see whether Novolog Pharm-Up 1966 is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. The company operates through three divisions: Logistics, Healthcare Services, and Digital.

Show moreShow less

The Logistics division engages in the import and distribution of pharmaceuticals and medical products; logistics of clinical trials and related services; provision of pharmaceutical services to customers; and sterilization and validation processes of consumable medical equipment.

The Healthcare Services division provides personalized medicine, medical and diagnostic laboratory, and other medical services to patients, health organizations, insurance companies, multinational companies, and government bodies.

The Digital division identifies and develops technological tools for health services; deals with making medical information accessible to the public through medical websites; promotes digital presence for clinics, doctors therapists, and medical bodies; provides services and management tools; and operates and markets digital platforms for doctors and clinics.

In addition, the company provides appointment scheduling, calendar management, and telemedicine meeting management. Novolog (Pharm-Up 1966) Ltd was incorporated in 1966 and is headquartered in Modi'in-Maccabim-Re'ut, Israel.

Stock analysis

Novolog Pharm-Up 1966 Ltd (NVLG) currently trades at 0.7830 ILS, while our model-based Fair Value estimate is 0.2900 ILS, 63% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of 1.22 ILS per share, and 2 of the 17 models we run sit above the 0.7830 ILS price.

Bear case: the Asset-Based group reads lowest at 0.0400 ILS, and 15 of the 17 models stay below the price. Data coverage for this calculation is low.

Scenario range: 0.2100 ILS (bear) to 0.3600 ILS (bull), the price of 0.7830 ILS sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Novolog Pharm-Up 1966 Ltd reported revenue of 1.8B ILS in FY2025 versus 1.3B ILS in FY2021, a compound +9.5%/yr. Reported net income was 4.1M ILS in FY2025, compounding −44.2%/yr from FY2021.

Key figures

Market cap 405M ILS Micro · P/E ratio 66.8 · P/S ratio 0.15 · Dividend yield 2.6% · Net margin 0.0% · Return on equity −0.2% · Return on assets (EBIT) 1.9% (5-year average) · Operating margin 2.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 19 out of 100 (low confidence).

What moves the price

The share trades about 42% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 33% fair-value upside, at −63%, NVLG screens richer than that median.

Fair Value models

Bear 0.2100 ILS Fair Value 0.2900 ILS Bull 0.3600 ILS
Price 0.7830 ILS · Downside -63.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings 0.8900 ILS 1.22 ILS 1.66 ILS 77
Residual Income 0.3700 ILS 0.3900 ILS 0.4300 ILS 76
EPV 0.5600 ILS 0.5900 ILS 0.6200 ILS 74
All 17 models by family
DCF Models
Owner Earnings 0.8900 ILS 1.22 ILS 1.66 ILS 77
Earnings-Based
Graham-Dodd 0.0500 ILS 0.2300 ILS 0.3100 ILS 64
Lynch FV 0.0600 ILS 0.0800 ILS 0.1100 ILS 61
PEG = 1.0 0.0600 ILS 0.0800 ILS 0.1100 ILS 57
EPV 0.5600 ILS 0.5900 ILS 0.6200 ILS 74
Dividend Discount
Gordon GGM 0.2600 ILS 0.4300 ILS 0.5500 ILS 68
DDM Multi-Stage 0.2600 ILS 0.4100 ILS 0.4600 ILS 67
Multiples
P/E Multiple 0.1300 ILS 0.1800 ILS 0.2200 ILS 63
P/S Multiple 0.1000 ILS 0.1400 ILS 0.1700 ILS 58
P/B Multiple 0.2100 ILS 0.2900 ILS 0.3600 ILS 55
EV/EBIT 0.5400 ILS 0.7600 ILS 0.9800 ILS 65
EV/EBITDA 1.95 ILS 2.64 ILS 3.33 ILS 67
EV/Revenue 0.3500 ILS 0.5500 ILS 0.7500 ILS 53
Asset-Based
NCAV (Graham) 0.0300 ILS 0.0400 ILS 0.0600 ILS 54
Economic Profit
Residual Income 0.3700 ILS 0.3900 ILS 0.4300 ILS 76
ROIC Compounder 0.5600 ILS 0.5900 ILS 0.6200 ILS 72
Growth Earnings
Growth-Adj P/E 0.1000 ILS 0.1400 ILS 0.1900 ILS 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 44/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 25
How much profit the company makes from its sales and capital
Quality Growth 40
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 29
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 75
How calm the share price moves, does not count
Price momentum 22
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 8
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 42/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−10.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
Start year 2020 (pandemic). Over 10 years: +10.2% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.5%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−34.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−37.2%
Dividend (yield on the price)2.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−37.2% vs −19.7%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 2%
Pace: the 5-year rate starts in 2020 (pandemic)

NVLG screens overvalued: fair value 63% below the price. Compare with McKesson Corporation →

Compare Novolog Pharm-Up 1966 Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 77 stocks

Beats the industry median on 2/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 44 · Below median
Fair Value upside −63.0% · Bottom 25%
Profitability
Return on assets 0.2% · Bottom 25%
Net margin (12 months) 0.0% · Bottom 25%
Operating margin (12 months) 2.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) 2.3% · Below median
Dividend yield (12 months) 2.6% · Below median

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/E (12 months) 66.8× · Priciest 25%
P/B 1.13× · Pricier than median
P/S (12 months) 0.22× · Cheaper than median
EV/EBITDA 4.0× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 38
FUTURE (revenue growth)12 · sector 24
PAST (return on equity)0 · sector 28
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)51 · sector 54

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Sinopharm Group 1099 HK$17.16 HK$51.48 +200% vs NVLG
Jointown Pharmaceutical Group 600998 ¥5.24 ¥11.56 +121% vs NVLG
Shanghai Pharmaceuticals Holding 601607 ¥16.76 ¥35.78 +113% vs NVLG
China National Medicines Corporation 600511 ¥29.29 ¥58.47 +100% vs NVLG
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥20.09 ¥26.64 +33% vs NVLG
Cencora, Inc COR $333.56 $341.58 +2% vs NVLG
Henry Schein, Inc HSIC $86.05 $78.69 −9% vs NVLG
McKesson Corporation MCK $1,061 $822.74 −22% vs NVLG
Galenica AG GALE CHF 89.45 CHF 61.79 −31% vs NVLG
Cardinal Health, Inc CAH $271.72 $163.14 −40% vs NVLG

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Novolog Pharm-Up 1966 Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Novolog Pharm-Up 1966 Ltd Fair Value". https://www.fairvalue-calculator.com/stock/NVLG

Frequently asked questions

Is Novolog Pharm-Up 1966 Ltd (NVLG) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 0.2900 ILS versus a price of 0.7830 ILS, about 63% lower (overvalued).
What is the fair value of NVLG?
Our model-based fair value for Novolog Pharm-Up 1966 Ltd is 0.2900 ILS (as of Nov 8, 2026), built from audited fundamentals. The current price: 0.7830 ILS.
What is the quality score of NVLG?
Novolog Pharm-Up 1966 Ltd has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Novolog Pharm-Up 1966 Ltd (NVLG)?
Our model-based price target is the fair value of 0.2900 ILS (as of Nov 8, 2026) from 17 valuation models. Cautious scenario 0.2100 ILS, optimistic scenario 0.3600 ILS. It is a calculation from audited fundamentals, not an analyst target.
What is the Novolog Pharm-Up 1966 Ltd stock forecast for 2026?
Our models put fair value at 0.2900 ILS, about 63% lower versus a price of 0.7830 ILS (overvalued). Cautious scenario 0.2100 ILS, optimistic scenario 0.3600 ILS. The calculation is refreshed regularly with new filings.
What is the revenue of Novolog Pharm-Up 1966 Ltd (NVLG)?
Novolog Pharm-Up 1966 Ltd reported trailing-twelve-month revenue of about 1.8B ILS (latest available figure, as of Nov 8, 2026).
Does Novolog Pharm-Up 1966 Ltd pay a dividend?
Novolog Pharm-Up 1966 Ltd currently shows a dividend yield of 2.55% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Novolog Pharm-Up 1966 Ltd (NVLG) and when is the ex-dividend date?
Novolog Pharm-Up 1966 Ltd pays a dividend of 0.02 ILS per share a year, a dividend yield of 2.6%. The last ex-dividend date was Dec 1, 2025. A dividend has been paid every year since at least 2018. Our assessment: Pays more than it earns. The company pays out more in dividends than it earns, and free cash flow clearly does not cover the dividend either. It may need to be cut unless profits recover.
What is the intrinsic value of Novolog Pharm-Up 1966 Ltd (NVLG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Novolog Pharm-Up 1966 Ltd it is 0.2900 ILS per share (as of Nov 8, 2026), against a price of 0.7830 ILS. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Novolog Pharm-Up 1966 Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, NVLG trades above its calculated fair value: price 0.7830 ILS, fair value 0.2900 ILS, a gap of about −63% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NVLG?
No. The price is what the market pays today (0.7830 ILS); the fair value is what the company's own numbers justify (0.2900 ILS). For Novolog Pharm-Up 1966 Ltd the two are 0.4930 ILS per share apart. That gap is exactly why we show both numbers side by side.
How much is Novolog Pharm-Up 1966 Ltd worth?
The market values Novolog Pharm-Up 1966 Ltd at about 405M ILS (market capitalisation, as of Nov 8, 2026). Per share that is 0.7830 ILS; our models calculate a fair value of 0.2900 ILS per share.
What do the bullish and bearish scenarios say about NVLG?
Our models span a range for Novolog Pharm-Up 1966 Ltd: cautious scenario 0.2100 ILS, base 0.2900 ILS, optimistic 0.3600 ILS per share (as of Nov 8, 2026, price 0.7830 ILS). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NVLG?
Novolog Pharm-Up 1966 Ltd trades at a price-to-earnings ratio of 66.8 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 0.2900 ILS is built from several models across several years. Median P/E at fiscal year-end, 8 fiscal years (2017 to 2025), reported earnings: 33.1. Other multiples: P/B 1.1, P/S 0.2, EV/EBITDA 4.0.
How solid is the balance sheet of Novolog Pharm-Up 1966 Ltd (NVLG)?
Balance-sheet figures for Novolog Pharm-Up 1966 Ltd (as of Nov 8, 2026): return on equity −0.2%. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is NVLG from its 52-week high?
Novolog Pharm-Up 1966 Ltd trades at 0.7830 ILS, about 42% below its 52-week high of 1.36 ILS and 17% above the low of 0.6680 ILS (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 0.2900 ILS is for.
Which stocks are comparable to Novolog Pharm-Up 1966 Ltd?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Novolog Pharm-Up 1966 Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price 0.7830 ILS, calculated fair value 0.2900 ILS (−63%), Quality Score 44/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NVLG calculated?
We run Novolog Pharm-Up 1966 Ltd through 17 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 0.2900 ILS builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Novolog Pharm-Up 1966 Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Novolog Pharm-Up 1966 Ltd (NVLG)?
The closing price on Nov 6, 2026 was 0.7830 ILS. Our model-based fair value is 0.2900 ILS, about 63% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Novolog Pharm-Up 1966 Ltd right now?
The price sits above even our optimistic bull case (0.3600 ILS). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Where does the earnings growth of Novolog Pharm-Up 1966 Ltd (NVLG) come from?
Earnings per share at Novolog Pharm-Up 1966 Ltd grew −5.6 % a year from 2014 to 2025. Broken into its drivers: revenue per share +7.1 %, EBIT margin −8.6 %, tax rate −0.6 %, residual (interest, one-offs) −3.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Novolog Pharm-Up 1966 Ltd

How large is the market capitalisation of Novolog Pharm-Up 1966 Ltd (NVLG)?
The market capitalisation of Novolog Pharm-Up 1966 Ltd is 405M ILS. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Novolog Pharm-Up 1966 Ltd (NVLG)?
The price-to-sales ratio of Novolog Pharm-Up 1966 Ltd is 0.15 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Novolog Pharm-Up 1966 Ltd (NVLG)?
The dividend yield of Novolog Pharm-Up 1966 Ltd is 2.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Novolog Pharm-Up 1966 Ltd (NVLG)?
The net margin of Novolog Pharm-Up 1966 Ltd is 0.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Novolog Pharm-Up 1966 Ltd (NVLG)?
The return on equity (ROE) of Novolog Pharm-Up 1966 Ltd is −0.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Novolog Pharm-Up 1966 Ltd (NVLG)?
On an EBIT basis the return on assets of Novolog Pharm-Up 1966 Ltd is 1.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Novolog Pharm-Up 1966 Ltd (NVLG)?
The operating margin of Novolog Pharm-Up 1966 Ltd is 2.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Novolog Pharm-Up 1966 Ltd (NVLG)?
Revenue at Novolog Pharm-Up 1966 Ltd is growing +2.3% versus a year earlier (3y avg +6.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Novolog Pharm-Up 1966 Ltd (NVLG)?
Earnings per share at Novolog Pharm-Up 1966 Ltd are growing −89.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Novolog Pharm-Up 1966 Ltd (NVLG) generate?
The free cash flow of Novolog Pharm-Up 1966 Ltd is −34.2M ILS (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Novolog Pharm-Up 1966 Ltd (NVLG) carry?
The net debt of Novolog Pharm-Up 1966 Ltd is 61.4M ILS (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Novolog Pharm-Up 1966 Ltd in the live analysis

One click puts Novolog Pharm-Up 1966 Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.